Specify a stock or a cryptocurrency in the search bar to get a summary
Harmony Biosciences Holdings
HRMYHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
Analytics
WallStreet Target Price
47.11 USDP/E ratio
17.0995Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HRMY
Dividend Analytics HRMY
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HRMY
Stock Valuation HRMY
Financials HRMY
Results | 2019 | Dynamics |